05.09.2019
- The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021. One important driver is the trend towards outsourcing of development and manu...
05.09.2019
- Swiss fine chemicals producer Lonza has signed a contract manufacturing agreement with Korea-based biosimilars producer Celltrion to supply a drug substance for Remsima, a...
15.07.2019
- Swiss fine chemicals producer and drug developer Lonza has completed a $15 million multi-phase expansion at its site in Tampa, Florida, USA, adding solid oral dose development and...
02.07.2019
- Swiss fine chemicals producer and drug developer Lonza has signed a binding agreement to acquire a sterile drug product fill & finish plant from Novartis, the first such facility...
04.06.2019
- Swiss fine chemicals company Lonza is carving out its specialty ingredients (LSI) segment under independent management, giving it increased control over operations and costs. LSI...
05.04.2019
- Swiss fine chemicals producer Lonza and Danish biosciences company Chr. Hansen are forming a 50:50 joint venture to develop and manufacture live biotherapeutic products (LBPs) for...
31.01.2019
- Richard Ridinger, CEO of Basel, Switzerland-based fine chemicals producer Lonza since April 2012, will retire at the end of February and be succeeded on Mar. 1 by Marc Funk...
12.12.2018
- Swiss-based Lonza is working with GE Healthcare, a General Electric subsidiary, to establish a biologics facility in Guangzhou, China. The deal will give Lonza a strategic base in...
